ProPhase Labs, Advanced Biological Laboratories Sign Letter of Intent for Reverse Merger

MT Newswires Live12-19

ProPhase Labs (PRPH) and Advanced Biological Laboratories said Friday they have signed a letter of intent for a proposed reverse merger under which Advanced Biological Laboratories would become the majority stakeholder in the combined company.

Under the proposed deal, the ProPhase business may have an enterprise value of up to about $30 million. Advanced Biological shareholders would own roughly 76% of the combined entity and the company would contribute its advanced data processing systems, cloud computing for health data, and financing capabilities, according to a statement.

Upon merger completion, a new US unit would hold and operate ProPhase's Nebula Genomics platform, BE-Smart Esophageal Cancer Test program, and select consumer health operations, according to the parties.

The transaction is still subject to due diligence, negotiation and execution of definitive agreements, the companies said, adding there is no guarantee that a deal would be reached.

Shares of ProPhase were up more than 71% in recent Friday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592167764?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592167764","market":"hk","top_or_hot":-1,"title":"ProPhase Labs, Advanced Biological Laboratories Sign Letter of Intent for Reverse Merger","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PRPH\">ProPhase Labs</a> (PRPH) and Advanced Biological Laboratories said Friday they have signed a letter of intent for a proposed reverse merger under which Advanced Biological Laboratories would become the majority stakeholder in the combined company.</p><p>Under the proposed deal, the ProPhase business may have an enterprise value of up to about $30 million. Advanced Biological shareholders would own roughly 76% of the combined entity and the company would contribute its advanced data processing systems, cloud computing for health data, and financing capabilities, according to a statement.</p><p>Upon merger completion, a new US unit would hold and operate ProPhase's Nebula Genomics platform, BE-Smart Esophageal Cancer Test program, and select consumer health operations, according to the parties.</p><p>The transaction is still subject to due diligence, negotiation and execution of definitive agreements, the companies said, adding there is no guarantee that a deal would be reached.</p><p>Shares of ProPhase were up more than 71% in recent Friday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProPhase Labs, Advanced Biological Laboratories Sign Letter of Intent for Reverse Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProPhase Labs, Advanced Biological Laboratories Sign Letter of Intent for Reverse Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-19 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PRPH\">ProPhase Labs</a> (PRPH) and Advanced Biological Laboratories said Friday they have signed a letter of intent for a proposed reverse merger under which Advanced Biological Laboratories would become the majority stakeholder in the combined company.</p><p>Under the proposed deal, the ProPhase business may have an enterprise value of up to about $30 million. Advanced Biological shareholders would own roughly 76% of the combined entity and the company would contribute its advanced data processing systems, cloud computing for health data, and financing capabilities, according to a statement.</p><p>Upon merger completion, a new US unit would hold and operate ProPhase's Nebula Genomics platform, BE-Smart Esophageal Cancer Test program, and select consumer health operations, according to the parties.</p><p>The transaction is still subject to due diligence, negotiation and execution of definitive agreements, the companies said, adding there is no guarantee that a deal would be reached.</p><p>Shares of ProPhase were up more than 71% in recent Friday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZL793.SGD","symbol_name":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592167764","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592167764","pubTimestamp":1766152307,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ProPhase Labs  and Advanced Biological Laboratories said Friday they have signed a letter of intent for a proposed reverse merger under which Advanced Biological Laboratories would become the majority stakeholder in the combined company.Under the proposed deal, the ProPhase business may have an enterprise value of up to about $30 million. Advanced Biological shareholders would own roughly 76% of the combined entity and the company would contribute its advanced data processing systems, cloud computing for health data, and financing capabilities, according to a statement.Upon merger completion, a new US unit would hold and operate ProPhase's Nebula Genomics platform, BE-Smart Esophageal Cancer Test program, and select consumer health operations, according to the parties.The transaction is still subject to due diligence, negotiation and execution of definitive agreements, the companies said, adding there is no guarantee that a deal would be reached.Shares of ProPhase were up more than 71%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK4007":"制药","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","PRPH":"ProPhase Labs","AEIS":"先进能源工业公司","BK4157":"电子设备和仪器"},"translate_title":"ProPhase Labs与Advanced Biological Laboratories签署反向合并意向书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRPH":1.5,"AEIS":1.5},"content_text":"ProPhase Labs (PRPH) and Advanced Biological Laboratories said Friday they have signed a letter of intent for a proposed reverse merger under which Advanced Biological Laboratories would become the majority stakeholder in the combined company.Under the proposed deal, the ProPhase business may have an enterprise value of up to about $30 million. Advanced Biological shareholders would own roughly 76% of the combined entity and the company would contribute its advanced data processing systems, cloud computing for health data, and financing capabilities, according to a statement.Upon merger completion, a new US unit would hold and operate ProPhase's Nebula Genomics platform, BE-Smart Esophageal Cancer Test program, and select consumer health operations, according to the parties.The transaction is still subject to due diligence, negotiation and execution of definitive agreements, the companies said, adding there is no guarantee that a deal would be reached.Shares of ProPhase were up more than 71% in recent Friday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592167764","isCrawlerRequest":true}